Please ensure Javascript is enabled for purposes of website accessibility

Trump Taps Former GlaxoSmithKline Exec For 'Warp Speed' COVID-19 Vaccine Initiative

By Cory Renauer – May 15, 2020 at 4:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GlaxoSmithKline's former head of pharmaceutical research and development will lead the Trump administration's coronavirus vaccine task force.

"Operation Warp Speed," the Trump administration's latest push to accelerate the development of a vaccine for SARS-CoV-2, has a new leader: Moncef Slaoui, the former head of pharmaceutical research and development at GlaxoSmithKline (GSK 1.52%)

Previously, Elias Zerhouni, a former Sanofi (SNY 2.37%) executive, had been expected to take the lead role. However, international outrage over recent comments from Sanofi's current CEO regarding that company's distribution plans for its own experimental SARS-CoV-2 vaccine -- should it prove effective -- probably figured into the administration's sudden change of plans.

Physician recording blood sample information.

Image source: Getty Images.

Slaoui will serve in a volunteer capacity with assistance from Gen. Gustave Perna, the current head of U.S. Army Materiel Command.  

A group effort

GlaxoSmithKline was a leading vaccine developer during Slaoui's tenure, which ended in 2017, and he hasn't left the field. He currently serves on the board of directors at Moderna (MRNA 3.87%), which is developing a SARS-CoV-2 vaccine candidate based on messenger RNA (mRNA).

Moderna's isn't the only mRNA vaccine under development that Operation Warp Speed aims to accelerate. Earlier this month, BioNTech (BNTX 0.65%) and its collaboration partner Pfizer (PFE 0.72%) began dosing patients with BNT162, which is actually four related mRNA vaccines bundled into one clinical development program -- the companies will soon select the best version to test in a larger population.

In addition to this pair of mRNA-based candidates, Operation Warp Speed will aim to assist with the development of coronavirus vaccine candidates from Sanofi, Johnson & Johnson, and AstraZeneca, just to name a few.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$125.67 (3.87%) $4.68
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.46 (0.72%) $0.32
Sanofi Stock Quote
Sanofi
SNY
$40.12 (2.37%) $0.93
GSK Stock Quote
GSK
GSK
$30.71 (1.52%) $0.46
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$57.04 (2.68%) $1.49
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.62 (1.48%) $2.42
BioNTech SE Stock Quote
BioNTech SE
BNTX
$137.57 (0.65%) $0.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.